Chugai Pharmaceutical (OTCMKTS:CHGCY) Hits New 12-Month Low – Should You Sell?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY)’s stock price reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $20.08 and last traded at $21.37, with a volume of 1439 shares. The stock had previously closed at $21.05.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on CHGCY. The Goldman Sachs Group upgraded Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Monday, June 15th. Nomura upgraded shares of Chugai Pharmaceutical to a “hold” rating in a research report on Tuesday, September 1st. Zacks Research raised shares of Chugai Pharmaceutical to a “hold” rating in a research note on Friday, May 29th. Finally, UBS Group lowered shares of Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy”.

Chugai Pharmaceutical Price Performance

The company has a 50-day moving average of $21.99 and a 200 day moving average of $24.92. The company has a market cap of $68.00 billion, a PE ratio of 22.46 and a beta of 0.59.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings data on Friday, July 24th. The company reported $0.22 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a return on equity of 23.76% and a net margin of 35.09%.The business had revenue of $2.14 billion for the quarter, compared to the consensus estimate of $2.38 billion. Equities research analysts expect that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 EPS for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Tokyo. Founded in 1925, the company focuses on discovering, developing, manufacturing and commercializing prescription medicines, with an emphasis on biotechnology and innovative therapies for serious and unmet medical needs.

Chugai’s principal therapeutic areas include oncology, hematology, immunology, neuroscience and renal diseases. Its products include Actemra (known as RoActemra in some markets) for inflammatory and immune-related conditions, Hemlibra for hemophilia A, and Alecensa for certain forms of lung cancer.